- Home
- TXO vs IVA Comparison
TXO vs IVA Comparison
Compare TXO & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- IVA
- Stock Information
- Founded
- TXO 2012
- IVA 2011
- Country
- TXO United States
- IVA France
- Employees
- TXO N/A
- IVA N/A
- Industry
- TXO Oil & Gas Production
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- IVA Health Care
- Exchange
- TXO Nasdaq
- IVA Nasdaq
- Market Cap
- TXO 788.9M
- IVA 769.0M
- IPO Year
- TXO 2023
- IVA 2020
- Fundamental
- Price
- TXO $14.01
- IVA $5.28
- Analyst Decision
- TXO Strong Buy
- IVA Strong Buy
- Analyst Count
- TXO 2
- IVA 6
- Target Price
- TXO $21.50
- IVA $15.33
- AVG Volume (30 Days)
- TXO 145.0K
- IVA 74.0K
- Earning Date
- TXO 11-04-2025
- IVA 09-26-2025
- Dividend Yield
- TXO 17.10%
- IVA N/A
- EPS Growth
- TXO N/A
- IVA N/A
- EPS
- TXO 0.30
- IVA N/A
- Revenue
- TXO $332,267,000.00
- IVA $14,591,573.00
- Revenue This Year
- TXO $31.08
- IVA $80.35
- Revenue Next Year
- TXO $11.32
- IVA N/A
- P/E Ratio
- TXO $47.41
- IVA N/A
- Revenue Growth
- TXO 15.94
- IVA N/A
- 52 Week Low
- TXO $13.28
- IVA $1.53
- 52 Week High
- TXO $20.70
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- TXO 49.14
- IVA 54.95
- Support Level
- TXO $13.42
- IVA $5.21
- Resistance Level
- TXO $13.88
- IVA $5.78
- Average True Range (ATR)
- TXO 0.29
- IVA 0.37
- MACD
- TXO 0.07
- IVA -0.09
- Stochastic Oscillator
- TXO 79.89
- IVA 9.56
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.